Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 2
1970 1
1972 1
1973 1
1974 3
1975 4
1976 1
1977 2
1978 3
1979 4
1980 6
1981 7
1982 7
1983 9
1984 10
1985 9
1986 8
1987 8
1988 17
1989 24
1990 12
1991 23
1992 22
1993 19
1994 34
1995 22
1996 42
1997 40
1998 48
1999 64
2000 86
2001 103
2002 125
2003 146
2004 205
2005 285
2006 331
2007 323
2008 367
2009 448
2010 550
2011 676
2012 706
2013 813
2014 815
2015 851
2016 949
2017 949
2018 987
2019 1051
2020 1148
2021 1147
2022 1051
2023 1006
2024 266

Text availability

Article attribute

Article type

Publication date

Search Results

13,987 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY. Meric-Bernstam F, et al. Among authors: lee jy. J Clin Oncol. 2024 Jan 1;42(1):47-58. doi: 10.1200/JCO.23.02005. Epub 2023 Oct 23. J Clin Oncol. 2024. PMID: 37870536 Free PMC article. Clinical Trial.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. Among authors: lee jy. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. Among authors: lee jy. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
The lipoprotein-associated phospholipase A2 inhibitor Darapladib sensitises cancer cells to ferroptosis by remodelling lipid metabolism.
Oh M, Jang SY, Lee JY, Kim JW, Jung Y, Kim J, Seo J, Han TS, Jang E, Son HY, Kim D, Kim MW, Park JS, Song KH, Oh KJ, Kim WK, Bae KH, Huh YM, Kim SH, Kim D, Han BS, Lee SC, Hwang GS, Lee EW. Oh M, et al. Among authors: lee jy. Nat Commun. 2023 Sep 15;14(1):5728. doi: 10.1038/s41467-023-41462-9. Nat Commun. 2023. PMID: 37714840 Free PMC article.
Man With Dyspnea.
Lee JY, Lin JW, Tsai TY. Lee JY, et al. Ann Emerg Med. 2023 Oct;82(4):e157-e158. doi: 10.1016/j.annemergmed.2023.04.007. Ann Emerg Med. 2023. PMID: 37739757 No abstract available.
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
Monk BJ, Toita T, Wu X, Vázquez Limón JC, Tarnawski R, Mandai M, Shapira-Frommer R, Mahantshetty U, Del Pilar Estevez-Diz M, Zhou Q, Limaye S, Godinez FJR, Oppermann Kussler C, Varga S, Valdiviezo N, Aoki D, Leiva M, Lee JY, Sulay R, Kreynina Y, Cheng WF, Rey F, Rong Y, Ke G, Wildsmith S, Lloyd A, Dry H, Tablante Nunes A, Mayadev J. Monk BJ, et al. Among authors: lee jy. Lancet Oncol. 2023 Dec;24(12):1334-1348. doi: 10.1016/S1470-2045(23)00479-5. Lancet Oncol. 2023. PMID: 38039991 Clinical Trial.
Clinical Practice Guideline for Percutaneous Endoscopic Gastrostomy.
Tae CH, Lee JY, Joo MK, Park CH, Gong EJ, Shin CM, Lim H, Choi HS, Choi M, Kim SH, Lim CH, Byeon JS, Shim KN, Song GA, Lee MS, Park JJ, Lee OY; Korean Society of Gastrointestinal Endoscopy Task Force on Clinical Practice Guidelines. Tae CH, et al. Among authors: lee jy. Gut Liver. 2024 Jan 15;18(1):10-26. doi: 10.5009/gnl230146. Epub 2023 Oct 18. Gut Liver. 2024. PMID: 37850251 Free PMC article. Review.
Carbon-based nanocomposites for biomedical applications.
Shin M, Lim J, Park Y, Lee JY, Yoon J, Choi JW. Shin M, et al. Among authors: lee jy. RSC Adv. 2024 Feb 28;14(10):7142-7156. doi: 10.1039/d3ra08946k. eCollection 2024 Feb 21. RSC Adv. 2024. PMID: 38419681 Free PMC article. Review.
13,987 results
You have reached the last available page of results. Please see the User Guide for more information.